Mubadala Investment Company and CBC Group have acquired full ownership of UCB Pharma’s mature business in China, focusing on neurology and allergy treatments along with a manufacturing site in Zhuhai. This move aligns with Mubadala’s strategy to boost its presence in Asia, particularly in the healthcare sector. The acquisition is part of a broader effort by UCB Pharma to grow its Central Nervous System (CNS) drug portfolio in China, a region with significant clinical demand in this therapeutic area. Earlier, Mubadala had partnered with CBC Group to invest $315 million in Hasten Biopharmaceutic. UCB’s sales in 2023 for this portfolio in China reached 131 million euros ($147 million). The deal is pending regulatory approvals and is expected to close by Q4 2024.
Healthcare, Pharmaceuticals, Private Equity,China, United Arab Emirates, Asia
https://www.zawya.com/en/wealth/wealth-management/abu-dhabi-fund-mubadala-invests-in-ucb-pharmas-china-carve-out-ybbl5bl9